Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5–10.
Google Scholar
Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002;1:97–104.
Google Scholar
Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics. 2008;121:e1470–1477.
Google Scholar
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216–31.
Google Scholar
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers 2019;5:1.
Hawkins DS, Spunt SL, Skapek SX, Committee COGSTS. Children’s Oncology Group’s 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer. 2013;60:1001–8.
Google Scholar
Kashi VP, Hatley ME, Galindo RL. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer. 2015;15:426–39.
Google Scholar
Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J. 2013;280:4323–34.
Google Scholar
Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, et al. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med. 2014;4:a025650.
Google Scholar
Zhu B, Davie JK. New insights into signalling-pathway alterations in rhabdomyosarcoma. Br J Cancer. 2015;112:227–31.
Google Scholar
Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14:369–81.
Google Scholar
Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, et al. NFkappaB signaling in alveolar rhabdomyosarcoma. Dis Model Mech. 2017;10:1109–15.
Google Scholar
Roma J, Masia A, Reventos J, Sanchez de Toledo J, Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res. 2011;17:505–13.
Google Scholar
Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, et al. The NOTCH1/SNAIL1/MEF2C pathway regulates growth and self-renewal in embryonal rhabdomyosarcoma. Cell Rep. 2017;19:2304–18.
Google Scholar
Singh S, Vinson C, Gurley CM, Nolen GT, Beggs ML, Nagarajan R, et al. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol. 2010;177:2055–66.
Google Scholar
Annavarapu SR, Cialfi S, Dominici C, Kokai GK, Uccini S, Ceccarelli S, et al. Characterization of Wnt/beta-catenin signaling in rhabdomyosarcoma. Lab Investig. 2013;93:1090–9.
Google Scholar
Satheesha S, Manzella G, Bovay A, Casanova EA, Bode PK, Belle R, et al. Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma. Oncogene. 2016;35:2020–30.
Google Scholar
Almazán-Moga A, Zarzosa P, Molist C, Velasco P, Pyczek J, Simon-Keller K, et al. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. Br J Cancer. 2017;117:1314–25.
Google Scholar
Ramadan F, Fahs A, Ghayad SE, Saab R. Signaling pathways in rhabdomyosarcoma invasion and metastasis. Cancer Metastasis Rev. 2020;39:287–301.
Google Scholar
Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012;2012:406239.
Google Scholar
Slemmons KK, Crose LES, Riedel S, Sushnitha M, Belyea B, Linardic CM. A novel notch-YAP circuit drives stemness and tumorigenesis in embryonal rhabdomyosarcoma. Mol Cancer Res. 2017;15:1777–91.
Google Scholar
Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211–26.
Google Scholar
Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Investig. 2014;124:285–96.
Google Scholar
Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell. 2014;26:273–87.
Google Scholar
Smit L, Baas A, Kuipers J, Korswagen H, van de Wetering M, Clevers H. Wnt activates the Tak1/Nemo-like kinase pathway. J Biol Chem. 2004;279:17232–40.
Google Scholar
Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell Death Differ. 2014;21:1667–76.
Google Scholar
Mukhopadhyay H, Lee NY. Multifaceted roles of TAK1 signaling in cancer. Oncogene. 2020;39:1402–13.
Google Scholar
Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.
Google Scholar
Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34:307–16.
Google Scholar
Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem. 2005;280:7359–68.
Google Scholar
Yu Y, Ge N, Xie M, Sun W, Burlingame S, Pass AK, et al. Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression. J Biol Chem. 2008;283:24497–505.
Google Scholar
Wen J, Hu Y, Luo KJ, Yang H, Zhang SS, Fu JH. Positive transforming growth factor-beta-activated kinase-1 expression has an unfavorable impact on survival in T3N1-3M0 esophageal squamous cell carcinomas. Ann Thorac Surg. 2013;95:285–90.
Google Scholar
Safina A, Sotomayor P, Limoge M, Morrison C, Bakin AV. TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res. 2011;9:1042–53.
Google Scholar
Iriondo O, Liu Y, Lee G, Elhodaky M, Jiménez C, Li L, et al. TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun. 2018;9:1994.
Google Scholar
Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH, et al. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-kappaB signaling. Oncotarget. 2014;5:7549–62.
Google Scholar
Roy A, Narkar VA, Kumar A. Emerging role of TAK1 in the regulation of skeletal muscle mass. Bioessays. 2023;45:e2300003.
Google Scholar
Hindi SM, Sato S, Xiong G, Bohnert KR, Gibb AA, Gallot YS, et al. TAK1 regulates skeletal muscle mass and mitochondrial function. JCI Insight. 2018;3:e98441.
Google Scholar
Hindi SM, Kumar A. TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis. J Clin Investig. 2016;126:151–68.
Google Scholar
Ogura Y, Hindi SM, Sato S, Xiong G, Akira S, Kumar A. TAK1 modulates satellite stem cell homeostasis and skeletal muscle repair. Nat Commun. 2015;6:10123.
Google Scholar
Bhatnagar S, Kumar A, Makonchuk DY, Li H, Kumar A. Transforming growth factor-beta-activated kinase 1 is an essential regulator of myogenic differentiation. J Biol Chem. 2010;285:6401–11.
Google Scholar
Tran P, Ho SM, Kim BG, Vuong TA, Leem YE, Bae GU, et al. TGF-beta-activated kinase 1 (TAK1) and apoptosis signal-regulating kinase 1 (ASK1) interact with the promyogenic receptor Cdo to promote myogenic differentiation via activation of the p38MAPK pathway. J Biol Chem. 2012;287:11602–15.
Google Scholar
Joshi AS, Tomaz da Silva M, Roy A, Koike TE, Wu M, Castillo MB, et al. The IRE1alpha/XBP1 signaling axis drives myoblast fusion in adult skeletal muscle. EMBO Rep. 2024;25:3627–50.
Google Scholar
Tomaz da Silva M, Roy A, Vuong AT, Joshi AS, Josphien C, Trivedi MV, et al. The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia. iScience. 2025;28:112714.
Google Scholar
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.
Google Scholar
Tomaz da Silva M, Joshi AS, Castillo MB, Koike TE, Roy A, Gunaratne PH, et al. Fn14 promotes myoblast fusion during regenerative myogenesis. Life Sci Alliance. 2023;6:e202302312.
Google Scholar
Gu Z, Hubschmann D. Make interactive complex heatmaps in R. Bioinformatics. 2022;38:1460–2.
Google Scholar
Coarfa C, Grimm SL, Rajapakshe K, Perera D, Lu HY, Wang X, et al. Reverse-phase protein array: technology, application, data processing, and integration. J Biomol Tech. 2021;32:15–29.
Google Scholar
Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668–81.
Google Scholar
Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995;270:2008–11.
Google Scholar
Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, et al. A CTC-cluster-specific signature derived from OMICS analysis of patient-derived xenograft tumors predicts outcomes in basal-like breast cancer. J Clin Med. 2019;8:1772.
Google Scholar
Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci USA. 2016;113:E6600–E6609.
Google Scholar
Abdulkareem NM, Bhat R, Qin L, Vasaikar S, Gopinathan A, Mitchell T, et al. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021;35:e21719.
Google Scholar
Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem. 2003;278:18485–90.
Google Scholar
Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.
Google Scholar
Sannino G, Marchetto A, Kirchner T, Grunewald TGP. Epithelial-to-mesenchymal and mesenchymal-to-epithelial transition in mesenchymal tumors: a paradox in sarcomas? Cancer Res. 2017;77:4556–61.
Google Scholar
Skovierova H, Okajcekova T, Strnadel J, Vidomanova E, Halasova E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med. 2018;41:1187–1200.
Google Scholar
Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376.
Google Scholar
Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012;109:E2441–2450.
Google Scholar
Huang FT, Peng JF, Cheng WJ, Zhuang YY, Wang LY, Li CQ, et al. MiR-143 targeting TAK1 attenuates pancreatic ductal adenocarcinoma progression via MAPK and NF-κB pathways in vitro. Dig Dis Sci. 2017;62:944–57.
Google Scholar
Graab U, Hahn H, Fulda S. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget. 2015;6:8722–35.
Google Scholar
Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2013;19:5940–51.
Google Scholar
Guenther MK, Graab U, Fulda S. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett. 2013;337:200–9.
Google Scholar
Mao H, Zhao X, Sun SC. NF-kappaB in inflammation and cancer. Cell Mol Immunol. 2025;22:811–39.
Google Scholar
Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res. 2014;2:823–30.
Google Scholar
Oles AR, Yu PY, Udeme AA, Sharma S, Londhe P, Pryce BR, et al. MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience. 2025;28:113149.
Google Scholar
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119:1420–8.
Google Scholar
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7:re8.
Google Scholar
Hernandez-Hernandez JM, Garcia-Gonzalez EG, Brun CE, Rudnicki MA. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. Semin Cell Dev Biol. 2017;72:10–18.
Google Scholar
Wardle FC. Master control: transcriptional regulation of mammalian Myod. J Muscle Res Cell Motil. 2019;40:211–26.
Google Scholar
Yang Z, MacQuarrie KL, Analau E, Tyler AE, Dilworth FJ, Cao Y, et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev. 2009;23:694–707.
Google Scholar
Li S, Chen K, Zhang Y, Barnes SD, Jaichander P, Zheng Y, et al. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Genes Dev. 2019;33:626–40.
Google Scholar
Buas MF, Kabak S, Kadesch T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. J Biol Chem. 2010;285:1249–58.
Google Scholar
Pomella S, Sreenivas P, Gryder BE, Wang L, Milewski D, Cassandri M, et al. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma. Nat Commun. 2021;12:192.
Google Scholar
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med. 2018;10:eaan4470.
Google Scholar
Slemmons KK, Crose LE, Rudzinski E, Bentley RC, Linardic CM. Role of the YAP oncoprotein in priming Ras-driven rhabdomyosarcoma. PLoS ONE. 2015;10:e0140781.
Google Scholar
Onodera Y, Teramura T, Takehara T, Fukuda K. Transforming growth factor beta-activated kinase 1 regulates mesenchymal stem cell proliferation through stabilization of Yap1/Taz proteins. Stem Cells. 2019;37:1595–605.
Google Scholar
Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, et al. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer. Mol Cancer Ther. 2020;19:247–57.
Google Scholar
